ICU Medical (NASDAQ:ICUI) Downgraded to Hold Rating by StockNews.com

StockNews.com lowered shares of ICU Medical (NASDAQ:ICUI) from a buy rating to a hold rating in a research note released on Tuesday.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. KeyCorp raised their price objective on ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Raymond James boosted their target price on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. Finally, Jefferies Financial Group initiated coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 2.1 %

Shares of NASDAQ:ICUI traded down $3.68 on Tuesday, hitting $168.28. The company had a trading volume of 29,811 shares, compared to its average volume of 274,502. The firm’s 50-day simple moving average is $176.32 and its two-hundred day simple moving average is $142.19. The company has a current ratio of 2.29, a quick ratio of 1.08 and a debt-to-equity ratio of 0.75. ICU Medical has a 1 year low of $82.82 and a 1 year high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.35. The firm had revenue of $580.07 million for the quarter, compared to the consensus estimate of $574.77 million. ICU Medical had a positive return on equity of 5.05% and a negative net margin of 4.74%. On average, equities analysts predict that ICU Medical will post 3.81 earnings per share for the current year.

Insiders Place Their Bets

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Friday, November 1st. The shares were sold at an average price of $171.84, for a total value of $2,062,080.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $17,973,261.12. This trade represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,502 shares of company stock valued at $6,573,496. Corporate insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ICUI. BNP Paribas Financial Markets raised its stake in ICU Medical by 55.3% during the 1st quarter. BNP Paribas Financial Markets now owns 4,552 shares of the medical instruments supplier’s stock worth $489,000 after acquiring an additional 1,620 shares during the period. Texas Permanent School Fund Corp lifted its stake in shares of ICU Medical by 1.4% during the 1st quarter. Texas Permanent School Fund Corp now owns 17,708 shares of the medical instruments supplier’s stock valued at $1,900,000 after buying an additional 243 shares in the last quarter. Sei Investments Co. boosted its holdings in ICU Medical by 52.1% in the 1st quarter. Sei Investments Co. now owns 28,586 shares of the medical instruments supplier’s stock worth $3,068,000 after buying an additional 9,793 shares during the period. Russell Investments Group Ltd. grew its position in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 173 shares in the last quarter. Finally, US Bancorp DE grew its holdings in ICU Medical by 18.2% during the 1st quarter. US Bancorp DE now owns 3,098 shares of the medical instruments supplier’s stock valued at $332,000 after buying an additional 476 shares in the last quarter. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.